Emerging drugs for the treatment of tuberculosis

Bibliography

• Global Alliance for TB Drug Development Scientific blue print for tuberculosis drug development. Tuberculosis 2001;81(Suppl 1):S1-52
   PubMedGoogle Scholar
• World Health Organization. Global tuberculosis control: a short update to the 2009 report. Geneva Switzerland 2009. WHO/HTM/TB/2009.426
   Google Scholar
• World Health Organization. Treatment of tuberculosis. Guidelines. Fourth Edition. Geneva Switzerland 2010. WHO/HTM/TB/2009.420
   Google Scholar
• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62
   PubMed Web of Science ®Google Scholar
• Chang KC, Leung CC, Yew WW, A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Repir Crit Care Med 2004;170:1124-30
   PubMed Web of Science ®Google Scholar
• Nahid P, Gonzalez LC, Rudoy I, Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007;175:1199-206
   PubMed Web of Science ®Google Scholar
• Yew WW, Leung CC. Management of multidrug-resistant tuberculosis: update 2007. Respirology 2008;13:21-46
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008;335:126-36
   PubMed Web of Science ®Google Scholar
• Mitnick CD, Castro KG, Harrington M, Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007;4:e292
   PubMed Web of Science ®Google Scholar
• Yew WW, Chan CK, Chau CH, Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin / levofloxacin-containing regimens. Chest 2000;117:744-51
   PubMed Web of Science ®Google Scholar
• Kim HR, Hwang SS, Kim HJ, Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007;45:1290-5
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis, state of the art. Int J Tuberc Lung Dis 2009;13:1320-30
   PubMed Web of Science ®Google Scholar
• Centers for Diseases Control and Prevention/American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2000;49:1-51
   PubMedGoogle Scholar
• Menzies D, Lobue PA. Treatment of latent tuberculosis infection: an update. Respirology 2010;15:603-22
   PubMed Web of Science ®Google Scholar
• Zhang Y. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 2005;45:529-64
   PubMed Web of Science ®Google Scholar
• Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-7
   PubMed Web of Science ®Google Scholar
• Cho SH, Warit S, Wan B, Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007;51:1380-5
   PubMed Web of Science ®Google Scholar
• Byrne ST, Gu P, Zhou J, Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007;51:4495-7
   PubMed Web of Science ®Google Scholar
• Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf 2002;25:111-33
   PubMed Web of Science ®Google Scholar
• Mitchison DA. The action of antituberculosis drugs in short course chemotherapy. Tubercle 1985;66:219-25
   PubMedGoogle Scholar
• Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3:S231-79
   PubMed Web of Science ®Google Scholar
• Zhang Y. Advances in the treatment of tuberculosis. Clin Pharmacol Ther 2007;82:595-600
   PubMed Web of Science ®Google Scholar
• Canetti G. The tubercle bacillus in the pulmonary lesion of man. Springer Publishing Company, New York; 1955
   Google Scholar
• McDermott W. Microbial persistence. Yale J Biol Med 1958;30:257-91
   PubMedGoogle Scholar
• Garg A, Barnes PF, Roy S, Mannose-capped lipoarabinomannan- and prostaglandin E2-dependent expansion of regulatory T cells in human Mycobacterium tuberculosis infection. Eur J Immunol 2008;38:459-69
   PubMed Web of Science ®Google Scholar
• Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 2010;14:241-2
   PubMed Web of Science ®Google Scholar
• Doherty TM, Wallis RS, Zumla A. Biomarkers of disease activity, cure and relapse in tuberculosis. Clin Chest Med 2009;30:783-96
   PubMed Web of Science ®Google Scholar
• Projan S. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003;6:427-30
   PubMed Web of Science ®Google Scholar
• Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003;7:6-21
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wade MM, Scorpio A, Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003;52:790-5
   PubMed Web of Science ®Google Scholar
• Hu Y, Coates AR, Mitchison DA. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008;12:69-73
   PubMed Web of Science ®Google Scholar
• Dahl JL, Kraus CN, Boshoff HI, The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci USA 2003;100:10026-31
   PubMed Web of Science ®Google Scholar
• Shi W, Zhang Y. PhoY2 but not PhoY1 is the PhoU homologue involved in persisters in Mycobacterium tuberculosis. J Antimicrob Chemother 2010;65:1237-42
   PubMed Web of Science ®Google Scholar
• Lin G, Li D, de Carvalho LP, Inhibitors selective for mycobacterial versus human proteasomes. Nature 2009;461:621-6
   PubMed Web of Science ®Google Scholar
• Andries K, Verhasselt P, Guillemont J, A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-7
   PubMed Web of Science ®Google Scholar
• Bryk R, Gold B, Venugopal A, Selective killing of nonreplicating mycobacteria. Cell Host Microbe 2008;3:137-45
   PubMed Web of Science ®Google Scholar
• Domingue GJ, Woody HB. Bacterial persistence and expression of disease. Clin Microbiol Rev 1997;10:320-44
   PubMed Web of Science ®Google Scholar
• Spigelman M, Woosley R, Ghevens J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis 2010;14:663-4
   PubMed Web of Science ®Google Scholar
• Nuermberger EL, Spigelman MK, Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology 2010. [Epub ahead of print]
   Google Scholar
• Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Eng J Med 2004; 351:1645-54
   PubMed Web of Science ®Google Scholar
• Benator D, Bhattacharya M, Bozeman L, ; Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 2002;360:528-34
   PubMed Web of Science ®Google Scholar
• Weiner M, Bock N, Peloquin CA, ; Tuberculosis Trials Consortium. Pharmacokinetics of rifapentine at 600, 900 and 1200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004;169:1191-7
   PubMed Web of Science ®Google Scholar
• Moadebi S, Harder CK, Fitzgerald MJ, Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67:2077-99
   PubMed Web of Science ®Google Scholar
• Johnson JL, Hadad DJ, Boom WH, Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-12
   PubMed Web of Science ®Google Scholar
• Burman WJ, Goldberg S, Johnson JL, Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-8
   PubMed Web of Science ®Google Scholar
• Conde MB, Efron A, Loredo C, Moxifloxacin versus ethambutol in the initial treatment of tuberculosis. A double-blind, randomized, controlled phase II trial. Lancet 2009;373:1183-9
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Lienhardt C, Kanyok T, Gatifloxacin for TB (OFLOTUB) study team. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-38
   PubMed Web of Science ®Google Scholar
• Dorman SE, Johnson JL, Goldberg S, Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-80
   PubMed Web of Science ®Google Scholar
• Weiner M, Burman W, Lou CC, Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007;51:2861-6
   PubMed Web of Science ®Google Scholar
• Xu P, Li X, Zhao M, Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother 2009;53:3170-2
   PubMed Web of Science ®Google Scholar
• Ibrahim M, Truffot-Pernot C, Andries K, Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009;180:553-7
   PubMed Web of Science ®Google Scholar
• Ibrahim M, Andries K, Lounis N. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007;51:1011-16
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Diacon AH, Allen J, Early bactericidal activity and pharmacokinetics of the diarylquinolone TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831-5
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch M, The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405
   PubMed Web of Science ®Google Scholar
• Lounis N, Gevers T, Van Den Berg J, Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 2008;52:3568-72
   PubMed Web of Science ®Google Scholar
• Veziris N, Ibrahim M, Lounis N, A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009;179:75-9
   PubMed Web of Science ®Google Scholar
• Lenaerts AJ, Gruppo V, Marietta KS, Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005;49:2294-301
   PubMed Web of Science ®Google Scholar
• Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol 2009;2:215-18
   PubMedGoogle Scholar
• Nuermberger E, Tyagi S, Tasneen R, Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;52:1522-4
   PubMed Web of Science ®Google Scholar
• Ginsberg AM, Laurenzi MW, Rouse DJ, Safety, tolerability and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 2009;53:3720-5
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, Hanekom M, Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010. [Epub ahead of print]
   Google Scholar
• Ginsberg AM, Laurenzi MW, Rouse DJ, Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob Agents Chemother 2009;53:3726-33
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Hashizume H, Tomishige T, OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466
   PubMed Web of Science ®Google Scholar
• Park IN, Hong SB, Oh YM, Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006;58:701-4
   PubMed Web of Science ®Google Scholar
• Migliori GB, Eker B, Richardson MD, A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009;34:387-93
   PubMed Web of Science ®Google Scholar
• Dietze R, Hadad DJ, McGee B, Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008;178:1180-5
   PubMed Web of Science ®Google Scholar
• Koh WJ, Kwon OJ, Gwak H, Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2009;64:388-91
   PubMed Web of Science ®Google Scholar
• Yew WW, Chang KC, Chau CH. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009;64:1119
   PubMed Web of Science ®Google Scholar
• Williams KN, Stover CK, Zhu T, Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009;53:1314-19
   PubMed Web of Science ®Google Scholar
• Wallis RS, Jakubiec WM, Kumar V. Pharmacokinetics and whole-blood bactericidal activity against Mycobaterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis 2010. [Epub ahead of print]
   Google Scholar
• Protopopova M, Hanrahan C, Nikonenko B, Identification of a new antitubercular drug candidate SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005;56:968-74
   PubMed Web of Science ®Google Scholar
• Chen P, Gearhart J, Protopopova M, Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006;58:332-7
   PubMed Web of Science ®Google Scholar
• Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new anti-tubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010;54:2840-6
   PubMed Web of Science ®Google Scholar
• Jia L, Tomaszewski JE, Hanrahan C, Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005;144:80-7
   PubMed Web of Science ®Google Scholar
• Jia L, Noker PE, Coward L, Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol 2006;147:476-85
   PubMed Web of Science ®Google Scholar
• Watt B, Edwards JR, Rayner A, In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tuber Lung Dis 1992;73:134-6
   PubMedGoogle Scholar
• Chambers HF, Turner J, Schecter GF, Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005;49:2816-21
   PubMed Web of Science ®Google Scholar
• Holzgrabe U. Meropenem-clavulanate: a new strategy for the treatment of tuberculosis? Chem Med Chem 2009;4:1051-3
   Web of Science ®Google Scholar
• Hugonett JE, Tremblay LW, Boshoff HI, Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009;323:1215-18
   PubMed Web of Science ®Google Scholar
• Martins M, Schelz Z, Martins A, In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int J Antimicrob Agents 2007;29:338-40
   PubMed Web of Science ®Google Scholar
• Martins M, Viveiros M, Kristiansen JE, The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 2007;21:771-5
   PubMed Web of Science ®Google Scholar
• Martins M, Viveiros M, Amaral L. Inhibitors of Ca2+ and K+ transport enhance intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo 2008;22:69-75
   PubMed Web of Science ®Google Scholar
• Amaral L, Martins M, Viveiros M, Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr Drug Targets 2008;9:816-19
   PubMed Web of Science ®Google Scholar
• Amaral L, Boeree MJ, Gillespie SH, Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 2010. [Epub ahead of print]
   Google Scholar
• Van Deun A, Maug AK, Salim MA, Highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010. [Epub ahead of print]
   Google Scholar
• Dheda K, Shean K, Zumla A, Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010;375:1798-807
   PubMed Web of Science ®Google Scholar
• Jacobson KR, Tierney DB, Jeon CY, Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010. [Epub ahead of print]
   Google Scholar
• Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets 2007;7:159-68
   PubMedGoogle Scholar